Is neutropenic fever an obstacle to effective stem cell harvesting?

Autor:	Başcı S; Department of Hematology and Bone Marrow Transplantation Center, Ankara, Turkey., Bozan E; Department of Hematology and Bone Marrow Transplantation Center, Ankara, Turkey., Yaman S; Department of Hematology and Bone Marrow Transplantation Center, Ankara, Turkey., Ulu BU; Department of Hematology and Bone Marrow Transplantation Center, Ankara, Turkey., Bakırtaş M; Department of Hematology and Bone Marrow Transplantation Center, Ankara, Turkey., Yiğenoğlu TN; Department of Hematology and Bone Marrow Transplantation Center, Ankara, Turkey., Kılınç A; Department of Hematology and Bone Marrow Transplantation Center, Ankara, Turkey., Özcan N; Department of Clinical Biochemistry, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey., Dal MS; Department of Hematology and Bone Marrow Transplantation Center, Ankara, Turkey., Çakar MK; Department of Hematology and Bone Marrow Transplantation Center, Ankara, Turkey., Altuntaş F; Department of Hematology and Bone Marrow Transplantation Center, Ankara, Turkey.
Jazyk:	angličtina
Zdroj:	Asian journal of transfusion science [Asian J Transfus Sci] 2024 Jan-Jun; Vol. 18 (1), pp. 21-26. Date of Electronic Publication: 2022 Sep 28.
DOI:	10.4103/ajts.ajts_152_21
Abstrakt:	Introduction: Autologous stem cell transplantation (ASCT) is a well-established consolidation treatment for many hematologic cancers which delivers prolonged survival. A subset of patients' adequate stem cell harvest is not achievable with a solitary use of granulocyte colony-stimulating agents (G-CSF). Generally, chemomobilization is employed for patients failing G-CSF and its most feared complication febrile neutropenia (FN). Materials and Methods: Here, we aimed to investigate the impact of the FN in chemomobilization on apheresis outcomes and engraftment. One hundred and eighty-three patients with the diagnosis of lymphoma or myeloma who underwent chemomobilization between 2015 and 2020 were included in the study. Results: Forty-three patients experienced FN. All patients received G-CSF. All myeloma patients were mobilized with 4 g/m 2 cyclophosphamide, but it was heterogeneous for lymphoma patients. The precollection blood counts, harvested CD34+ hematopoietic stem cells (HSCs)/kg, apheresis count, and engraftment durations were recorded. Preapheresis leukocyte and platelet were lower in the FN group ( P = 0,004 and P = 0,001). Peripheral CD34 HSCs and total harvested CD34 HSCs were similar among groups ( P = 0.25 and P = 0.9). More apheresis was needed in the FN group, but it was not significant ( P = 0.07). Undergoing ASCT was similar ( P = 0.7); however, platelet and neutrophil engraftment durations were slower in the FN group ( P = 0.05 and P = 0.001). Conclusion: Harvesting sufficient CD34+ HSCs from patients with FN is still feasible; however, FN treatment should begin promptly, and further apheresis sessions may be required. Competing Interests: There are no conflicts of interest. (Copyright: © 2022 Asian Journal of Transfusion Science.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu